• Home
  •  / vTv Therapeutics

vTv Therapeutics

OverviewSuggest Edit

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. vTv Therapeutics' type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. The Company has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

TypePublic
Founded1998
HQHigh Point, NC, USMap
Websitevtvtherapeutics.com

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)26(-50%)
Revenue (FY, 2019)$2.8 M(-77%)
Share Price (Jan 2021)$2.1 (-2%)
Cybersecurity ratingAMore

Key People/Management at vTv Therapeutics

Carmen Valcarce

Carmen Valcarce

Executive Vice President, Chief Scientific Officer

vTv Therapeutics Office Locations

vTv Therapeutics has an office in High Point
High Point, NC, US (HQ)
3980 Premier Dr #310
High Point, NC, US
4170 Mendenhall Oaks Pkwy
Show all (2)

vTv Therapeutics Financials and Metrics

vTv Therapeutics Revenue

vTv Therapeutics's revenue was reported to be $2.76 m in FY, 2019
USD

Revenue (Q3, 2020)

7.0k

Net income (Q3, 2020)

(2.3m)

EBIT (Q3, 2020)

(2.8m)

Market capitalization (15-Jan-2021)

158.3m

Closing stock price (15-Jan-2021)

2.1

Cash (30-Sept-2020)

1.8m

EV

159.7m
vTv Therapeutics's current market capitalization is $158.3 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

519.0k634.0k291.0k12.4m2.8m

Revenue growth, %

22%

General and administrative expense

9.1m9.9m11.3m9.2m8.5m

R&D expense

27.2m45.0m39.6m23.0m15.1m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

110.0k133.0k376.0k182.0k38.0k30.0k13.0k15.0k2.1m2.5m3.4m921.0k1.8m8.0k8.0k7.0k

General and administrative expense

2.3m2.4m2.6m2.7m2.4m2.8m3.0m2.6m2.3m2.7m2.2m2.4m2.4m1.8m2.5m1.7m1.1m

R&D expense

5.1m6.6m11.1m12.1m10.6m11.0m9.6m9.0m8.9m8.6m2.7m2.8m4.2m3.7m4.2m2.5m1.8m

Operating expense total

7.4m9.0m13.7m14.7m13.0m13.8m12.6m11.6m11.2m11.3m4.9m5.2m6.6m5.4m6.7m4.2m2.8m
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

88.0m51.5m11.8m1.7m1.8m

Accounts Receivable

8.0m5.0k

Prepaid Expenses

442.0k666.0k806.0k

Inventories

1.1m612.0k
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

97.0m75.5m63.8m51.1m45.2m32.5m20.5m6.5m1.2m3.8m5.0m1.5m2.4m406.0k6.4m1.8m

Accounts Receivable

206.0k210.0k2.3m1.8m10.0k5.0k14.0k

Prepaid Expenses

799.0k1.3m423.0k1.1m782.0k639.0k725.0k471.0k264.0k1.0m419.0k145.0k870.0k591.0k299.0k1.3m

Current Assets

97.8m77.1m64.3m52.1m45.9m33.2m21.5m9.5m6.0m5.9m5.4m3.8m3.6m3.5m6.8m3.7m
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(54.6m)(23.8m)(21.9m)

Depreciation and Amortization

501.0k265.0k197.0k218.0k39.0k

Inventories

5.5m

Accounts Payable

2.9m4.8m2.4m(6.2m)(618.0k)
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(30.0m)(13.5m)(28.1m)(41.6m)(14.3m)(27.7m)(40.1m)(10.0m)(19.6m)(21.5m)(4.0m)(9.1m)(15.1m)(7.2m)(12.2m)(14.4m)

Depreciation and Amortization

361.0k79.0k148.0k216.0k52.0k104.0k152.0k42.0k81.0k111.0k8.0k16.0k24.0k27.0k49.0k72.0k

Accounts Payable

1.5m1.3m2.9m3.4m(308.0k)(679.0k)(1.3m)(2.6m)(757.0k)(4.9m)(1.4m)635.0k(788.0k)331.0k(384.0k)(1.4m)

Cash From Operating Activities

(28.0m)(12.5m)(24.1m)(36.8m)(13.8m)(26.5m)(38.5m)(5.4m)(14.7m)(21.0m)(5.4m)(10.9m)(17.1m)(5.6m)(10.4m)(15.8m)
show all
Show all financial metrics

vTv Therapeutics Operating Metrics

FY, 2016

Phase I Trials Products

2

Phase II Trials Products

2

Phase III Trials Products

1
Show all operating metrics

vTv Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

Learn more about our premium products
SecurityScorecard logo

vTv Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

Learn more about our premium products
CSRHub logo

vTv Therapeutics Online and Social Media Presence

vTv Therapeutics's Trends

Embed Graph

vTv Therapeutics News and Updates

January 06, 2021

vTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Virtually

HIGH POINT, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced that it is participating in the LifeSci Pa…
December 15, 2020

Thinking about buying stock in Anavex Life Sciences, Veru Inc, vTv Therapeutics, BioCardia, or 22nd Century Group?

NEW YORK, Dec. 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVXL, VERU, VTVT, BCDA, and XXII. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
December 15, 2020

vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio

HIGH POINT, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC (“vTv”) has entered into a licensing agreement with Anteris Bio for worldwide rights to vTv’s novel clinical-stage Nrf2 activator compound, HPP971. Anteris Bio, a newly…
December 11, 2020

Thinking about buying stock in Walt Disney, vTv Therapeutics, 22nd Century Group, Lexicon Pharmaceuticals, or Ardelyx?

NEW YORK, Dec. 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DIS, VTVT, XXII, LXRX, and ARDX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
November 24, 2020

vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital

HIGH POINT, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) for up to $47 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor.
November 05, 2020

vTv Therapeutics Announces 2020 Third Quarter Financial Results and Update

HIGH POINT, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2020, and provided an update on the progress of its clinical programs.
Show more

vTv Therapeutics Blogs

November 04, 2020

vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study

HIGH POINT, N.C. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) today reported baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of azeliragon as a potential treatment for mild Alzheimer’s disease (AD) in people with type 2 diabetes
July 27, 2020

vTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study of Azeliragon at the Virtual Alzheimer's Association International Conference

HIGH POINT, N.C. , July 27, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc . (Nasdaq: VTVT) today announced that the Company will present at the upcoming 2020 Alzheimer's Association International Conference (AAIC), held virtually, July 27–31, 2020. The poster presentation will highlight additional
June 13, 2020

vTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association’s Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients

vTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association’s Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients Content Import Sat, 06/13/2020 - 11:00 vTv Ther…
May 27, 2020

vTv Therapeutics to Present Full Clinical Study Results from the Positive Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes at the American Diabetes Association’s 80th Virtual Scientifi

HIGH POINT, N.C. , May 27, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) today announced that two late-breaking abstracts reinforcing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes will be presented virtually at the American Diabetes Association’s 80th
May 22, 2020

vTv Therapeutics Changes its 2020 Annual Meeting of Stockholders to Virtual Format

vTv Therapeutics Changes its 2020 Annual Meeting of Stockholders to Virtual Format Content Import Fri, 05/22/2020 - 16:30 vTv Therapeutics Changes its 2020 Annual Meeting of Stockholders to Virtual Format May 22, 2020 at 4:30 PM EDT This release is a backfill …
May 07, 2020

vTv Therapeutics Announces 2020 First Quarter Financial Results and Update

vTv Therapeutics Announces 2020 First Quarter Financial Results and Update Content Import Thu, 05/07/2020 - 16:31 vTv Therapeutics Announces 2020 First Quarter Financial Results and Update May 7, 2020 at 4:30 PM EDT This release is a backfill from a News Wire …
Show more

 vTv Therapeutics Frequently Asked Questions

  • When was vTv Therapeutics founded?

    vTv Therapeutics was founded in 1998.

  • Who are vTv Therapeutics key executives?

    vTv Therapeutics's key executives are Carmen Valcarce.

  • How many employees does vTv Therapeutics have?

    vTv Therapeutics has 26 employees.

  • What is vTv Therapeutics revenue?

    Latest vTv Therapeutics annual revenue is $2.8 m.

  • What is vTv Therapeutics revenue per employee?

    Latest vTv Therapeutics revenue per employee is $106.3 k.

  • Who are vTv Therapeutics competitors?

    Competitors of vTv Therapeutics include NGM Biopharmaceuticals, Aimmune Therapeutics and Ampio Pharmaceuticals.

  • Where is vTv Therapeutics headquarters?

    vTv Therapeutics headquarters is located at 3980 Premier Dr #310, High Point.

  • Where are vTv Therapeutics offices?

    vTv Therapeutics has an office in High Point.

  • How many offices does vTv Therapeutics have?

    vTv Therapeutics has 2 offices.